完整標題：
Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two
COVID-19 Vaccines for Older and Immunocompromised Individuals
發稿單位：美國FDA
發稿時間：March 29, 2022
撰 稿 者：美國FDA
原文連結：https://bit.ly/3wMHcv2
FDA在今日(3/29)核准輝瑞BNT和莫德納的第二追加劑(second booster dose)
施打的目標對象群是長者跟特定的免疫力低下族群
之前FDA已經核准了一劑追加劑，施打在已施打完基礎加強劑的目標群上
本次核准透過施打第二追加劑，
將能夠對那些重症高危險群提供更多的免疫保護力，避免重症住院甚至死亡。
目前的證據指出第二追加劑可以提供更高的保護力，無任何新的安全疑慮。
Today, the U.S. Food and Drug Administration authorized a second booster dose
of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older
people and certain immunocompromised individuals. The FDA previously
authorized a single booster dose for certain immunocompromised individuals
following completion of a three-dose primary vaccination series. This action
will now make a second booster dose of these vaccines available to other
populations at higher risk for severe disease, hospitalization and death.
Emerging evidence suggests that a second booster dose of an mRNA COVID-19
vaccine improves protection against severe COVID-19 and is not associated
with new safety concerns.
可接受施打的對象(疫苗標準參照美國FDA/CDC標準)：
1.50歲以上的成年人
且完成第一次追加劑接種4個月後
2.曾因為接受器官移植等造成免疫力低下
且完成第一次追加劑接種4個月後
(輝瑞BNT年齡12歲以上、莫德納18歲以上)
The agency amended the emergency use authorizations as follows:
A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna
COVID-19 Vaccine may be administered to individuals 50 years of age and older
at least 4 months after receipt of a first booster dose of any authorized or
approved COVID-19 vaccine.
A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be
administered to individuals 12 years of age and older with certain kinds of
immunocompromise at least 4 months after receipt of a first booster dose of
any authorized or approved COVID-19 vaccine. These are people who have
undergone solid organ transplantation, or who are living with conditions that
are considered to have an equivalent level of immunocompromise.
A second booster dose of the Moderna COVID-19 Vaccine may be administered
at least 4 months after the first booster dose of any authorized or approved
COVID-19 vaccine to individuals 18 years of age and older with the same
certain kinds of immunocompromise.
(其餘段落省略)